These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Metabolic side effects of risperidone in early onset schizophrenia]. Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267 [TBL] [Abstract][Full Text] [Related]
4. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. Newcomer JW CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156 [TBL] [Abstract][Full Text] [Related]
5. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related]
7. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Sikich L; Frazier JA; McClellan J; Findling RL; Vitiello B; Ritz L; Ambler D; Puglia M; Maloney AE; Michael E; De Jong S; Slifka K; Noyes N; Hlastala S; Pierson L; McNamara NK; Delporto-Bedoya D; Anderson R; Hamer RM; Lieberman JA Am J Psychiatry; 2008 Nov; 165(11):1420-31. PubMed ID: 18794207 [TBL] [Abstract][Full Text] [Related]
8. Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies. Bernardo M; Rico-Villademoros F; García-Rizo C; Rojo R; Gómez-Huelgas R Adv Ther; 2021 May; 38(5):2491-2512. PubMed ID: 33826090 [TBL] [Abstract][Full Text] [Related]
9. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512 [TBL] [Abstract][Full Text] [Related]
11. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM; Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369 [TBL] [Abstract][Full Text] [Related]
12. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation]. Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I Encephale; 2005; 31(2):235-46. PubMed ID: 15959450 [TBL] [Abstract][Full Text] [Related]
13. [Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone]. Bret P; Bonnet F; Bret MC; Jaffré A Encephale; 2002; 28(4):329-42. PubMed ID: 12232542 [TBL] [Abstract][Full Text] [Related]
14. Quetiapine versus other atypical antipsychotics for schizophrenia. Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315 [TBL] [Abstract][Full Text] [Related]
15. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Citrome L; Holt RI; Walker DJ; Hoffmann VP Clin Drug Investig; 2011; 31(7):455-82. PubMed ID: 21495734 [TBL] [Abstract][Full Text] [Related]
16. Prevalence and Management of Metabolic Syndrome in Adult Psychiatric Patients Receiving Second-Generation Antipsychotics at Sheikh Khalifa Medical City. Mohammed W; Al Naeem W Cureus; 2022 Feb; 14(2):e22021. PubMed ID: 35282550 [TBL] [Abstract][Full Text] [Related]
17. [Schizophrenia, diabetes mellitus and antipsychotics]. Gury C Encephale; 2004; 30(4):382-91. PubMed ID: 15538314 [TBL] [Abstract][Full Text] [Related]
18. New generation antipsychotics for first episode schizophrenia. Rummel C; Hamann J; Kissling W; Leucht S Cochrane Database Syst Rev; 2003; (4):CD004410. PubMed ID: 14584012 [TBL] [Abstract][Full Text] [Related]
19. Management of schizophrenia with obesity, metabolic, and endocrinological disorders. Monteleone P; Martiadis V; Maj M Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883 [TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients. Chadda RK; Ramshankar P; Deb KS; Sood M J Pharmacol Pharmacother; 2013 Jul; 4(3):176-86. PubMed ID: 23960422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]